


SETTLEMENTS OF ACCOUNTS

From 1st April 2021
to 31th March 2022

Concord Biotech Japan K.K.


Atsushi SATO, President

OHMURA Tax Account Office
2029-2 Ichihama, Numazu, Shizuoka, JAPAN



BALANCE SHEETS

As at 31th March 2022

CONCORD BIOTECH JAPAN K.K.

JPY

Assets		Liabilities	
<u>Current assets</u>	403,817,676	<u>Current liabilities</u>	232,671,042
Cash and deposit	96,345,488	Account payable-trade	231,000,000
Promissory notes [Receivable]	83,160,000	Short-term borrowing	500
Account Receivable	52,500,000	Accounts payable	337,410
Allowance for doubtful accounts	-1,356,600	Accrued expenses	274,957
Promissory notes [Discounted]	-41,580,000	Deposits payable	1,058,175
Product inventory	200,458,512		
Prepaid expenses	787,947		
Temporary payment	7,700,000	<u>Long-term liabilities</u>	92,255,180
Accrued consumption tax	5,802,329	Long-term borrowings	92,255,180
	4,592,229	Liabilities total:	324,926,222
<u>Fixed assets</u>		<u>Net Equity</u>	
Fixed assets	156,449	<u>Stockholders equity</u>	83,483,683
Machinery	156,449	Capital	20,000,000
<u>Investment and other assets</u>	4,435,780	Accumulated earnings	63,483,683
Capital	10,000	Other accumulated earnings	63,483,683
Guarantee deposits	4,425,780	Brought down accumulated earnings	63,483,683
		(Net gain of current period)	24,460,129
		Net equity total	83,483,683
Asset total:	408,409,905	Liabilities and net equity total:	408,409,905

Atsushi Sato



INCOME STATEMENT

From 1st April 2021 to 31th March 2022

CONCORD BIOTECH JAPAN K.K.

JPY

<u>Net sales</u>		
Amount of sales	230,800,000	
Overseas sales	420,000,000	
Net sales total		650,800,000
<u>Cost of sales</u>		
Opening [Initial] Inventory	46,261,176	
Imported Purchases	357,800,000	
Import charges	441,353	
Import inspection	115,539	
Export charges	755,406	
Overseas Purchases	354,200,000	
Total	759,573,474	
Closing [End] Inventory	200,458,512	
Cost of sales		559,114,962
Gross profit		91,685,038
<u>Selling, general & administrative expenses</u>		
Total of selling, general & administrative expenses		68,663,990
Sales gain		23,021,048
<u>Non-operating gain</u>		
Interest received	1,025	
Divident received	250	
Miscellaneous income	22,081	
Non-operating gain total		23,356
<u>Non-operating loss</u>		
Interest paid	68,910	
Discount expense	303,165	
Non-operating loss total		372,075
Ordinary gain		22,672,329
<u>Non-operating loss</u>		
Reversal of allowance for doubtful accounts	1,787,800	
Extoraordinary gain total		1,787,800
Gain of income before income tax		24,460,129
Net gain		24,460,129

Atsushi Sato



Selling, General & Administrative Expenses

From 1st April 2021 to 31th March 2022

CONCORD BIOTECH JAPAN K.K.

JPY

Payments for directors, A.Sato and Utako Sato	22,410,000	
Salary	21,051,000	
Contribution to Health Insurance & Pension Fund	1,662,044	
Welfare expense	22,421	
Transportation	126,355	
Advertising expenses	1,156,440	
Traveling expenses	638,061	
Communications	255,611	
Office Supplies [like Printing & Stationery etc.]	796,961	
Utilities	246,064	
Bank charges	494,506	
Drug regulatory expenses	58,465	
Payments to Consultants	614,000	
Depreciation expenses	78,106	
Office rent	3,780,000	
Taxes, Stamp Duty on Promissory Notes and Oth	13,900,106	
Provision of allowance for doubtful accounts	1,356,600	
Maintenance fee	17,250	
Total:		68,663,990